Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Hubbell (HUBB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Hubbell — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $112.3 (market cap $12.58B), while Hubbell trades at $474.82 (market cap $25.12B). The key difference: Hubbell is the larger of the two by market cap, and Hubbell pays a 1.19% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 0 Days and Hubbell for 3 Days on average.
| HALO | HUBB | |
|---|---|---|
Market Cap | $12.58B | $25.12B |
Volume | 2,179,278 | 784,557 |
Sector | Health | Industrials |
52-Week High | $115.22 | $557.85 |
52-Week Low | $61.63 | $407.36 |
Typical Hold Time | 0 Days | 3 Days |
Enterprise Value | $14.49B | $30.28B |
Dividend Yield | — | 1.19% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Hubbell
Hubbell manufactures electrical and utility products used in transmission, distribution, and electrical infrastructure. Its portfolio includes components and systems for utilities, data centers, industrial facilities, and buildings.
Read more on HUBB →
